Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
3 Oversold Biotech Names
12:56pm, Monday, 13'th Jan 2025
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
12:53pm, Monday, 23'rd Dec 2024
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise fac
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:15pm, Tuesday, 17'th Dec 2024
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Confer
Jazz Pharmaceuticals Announces CEO Succession Plan
04:05pm, Monday, 16'th Dec 2024
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Fo
5 High ROE Stocks to Buy as Volatility Weighs on Markets
10:26am, Wednesday, 11'th Dec 2024
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improv
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , De
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
04:15pm, Wednesday, 04'th Dec 2024
DUBLIN , Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m.
Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , De
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
10:57am, Friday, 29'th Nov 2024
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
01:11pm, Thursday, 21'st Nov 2024
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
07:59pm, Wednesday, 20'th Nov 2024
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate a
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
04:05pm, Tuesday, 19'th Nov 2024
DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will pa
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
10:45am, Tuesday, 19'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
